Date:6/25/2010

t any time. In the event such risks or uncertainties materialize, the company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the company's products; the company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the company's products; the company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations:

    Clea Rosenfeld (Rest of the World), +44-1256-894-160;
    Eric Rojas (North America), +1-617-551-9715.

    Media:

    Jessica Mann (Rest of the World), +44-1256-894-280;
    Jessica Cotrone (North America, HGT), +1-781-482-9538.

'/>"/>

SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Shire plc Appoints Two New Board Directors
2. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
3. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
4. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
5. Shires Replenished Portfolio Drives Excellent Quarterly Performance
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Shire Supports Rare Disease Day 2010
8. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
9. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
10. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
11. New Shire Board Member